New cancer drug trial halted early – what we know
Disease control
Terminated
This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system fight cancer by targeting PD-1 and delivering an immune-boosting protein (IL-18). The …
Phase: PHASE1 • Sponsor: Bright Peak Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC